Browsing by Author "Parmanande, A"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Bladder Cancer New Biomarkers in Liquid BiopsiesPublication . Falcão, G; Barreira, JV; Parmanande, A; Carneiro, C; Campos Pinheiro, LBladder cancer is one of the most common neoplasia in men in the developed countries. Diagnosis and surveillance are made by bladder examination through cystoscopy making this one of the most expensive on cost/patient. After tumor removal, clinical staging is important for prognosis and treatment decision as non-muscle invasive (Ta and T1) and invasive (T2+) are treated in a completely different way. Today no noninvasive method has enough sensitivity to substitute cystoscopy or histological examination for tumor clinical staging. Our aim is to identify and quantify in urine, proteins that can detect and classify bladder tumors. A biomarker study was conducted using urine samples from: individuals with bladder cancer; individuals with other genitourinary disorders and individuals without urological diseases. Several proteins were found to successfully help in the discrimination of the bladder cancer stages Ta, T1 and T2+. Two biomarkerpanels were developed, one capable of detecting bladder cancer presence and other able to distinguish Ta, T1 and T2+. Our results show a significant difference between urinary proteome in patients with different bladder cancer stages. This may allow through liquid biopsies predict patient’s cancer stage. A validation study is on progress to attest this biomarker panel’s accuracy.
- Full Recovery of a Stage IV Cancer Patient Facing COVID-19 PandemicPublication . Parmanande, A; Simão, D; Sardinha, M; Palma dos Reis, AF; Spencer, AS; Barreira, JV; Luz, RCoronavirus disease 2019 (COVID-19), first recognized in Wuhan, China, was recently declared a global pandemic by the World Health Organization (WHO). Advanced age and comorbid disease, well-known characteristics in the solid tumor population, have been reported as risk factors for severe disease and death. Cancer-related immunosuppression and its treatments also seem to play an active role in the prognosis, response, and clinical outcomes of these patients. The most effective combination therapy for COVID-19 is still under investigation, and the use of corticosteroids is controversial. Although, as a group, metastatic cancer patients are often considered not to be good candidates for ICU treatment, the individual prognosis should always come into consideration, even in a context of high pressure on medical facilities. We report the case of a stage IV prostate cancer patient infected with SARS-CoV-2 who required ICU admission and recovered from COVID-19 infection. Further studies are needed in order to identify accurate clinical prognostic criteria and provide the best treatment for these challenging patients.
- Personalized Medicine: Paradigm Shift in ALK Positive Non-Small Cell Lung Cancer: a Case ReportPublication . Barreira, JV; Leão Mendes, J; Parmanande, ABackground: Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved. In order to guarantee the possibility of longer survival outcomes with a better quality of life we must invest in the determination, in suitable time, of the consensual biomarkers and in the availability of the best treatments to our patients. Case presentation: We present a case of a caucasian male in his fifth decade of life, non-smoker, who highlights the complex journey of ALK-positive patients. This particular case, demonstrates the efficacy and tolerability of the new ALK target therapies, allowing our patients to maintain their routines without compromising the effectiveness of the therapy. Conclusion: Focusing on the reality of ALK positive patients and the impact that this therapy has on the daily lives of our patients, we can contribute to the awareness of this specific pathology.